<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128410</url>
  </required_header>
  <id_info>
    <org_study_id>2019PHB169-01</org_study_id>
    <nct_id>NCT04128410</nct_id>
  </id_info>
  <brief_title>A Study on Central Transport Characteristics of Flurbiprofen Axetil in Elderly Patients</brief_title>
  <official_title>A Study on Central Transport Characteristics of Flurbiprofen Axetil in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yi Feng, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project will apply the methods of clinical observation experiment to study the central
      transport characteristics of flurbiprofen axetil by detecting S-flurbiprofen and
      R-flurbiprofen concentrations in cerebral-spinal fluid(CSF) after intravenous injection of
      flurbiprofen axetil in elderly patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients undergoing spinal anesthesia for lower extremity surgery will be studied.
      Flurbiprofen axetil 100mg will be injected intravenously. CSF 1ml and blood 2ml will be
      obtained simultaneously every 5 minutes after intravenous injection in 50 min( T1~T10).CSF
      and blood samples will be used to detected S-flurbiprofen and R-flurbiprofen concentrations
      by using Liquid Chromatography-Mass Spectrometry. And the CSF/blood S-flurbiprofen and
      R-flurbiprofen concentrations ratio were calculated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The concentrations of S-flurbiprofen and R-flurbiprofen in plasma and CSF of all patients.</measure>
    <time_frame>perioperation</time_frame>
    <description>The samples will be used to be determined plasma and CSF drug concentrations.</description>
  </primary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Flurbiprofen Axetil</condition>
  <condition>Cerebrospinal Fluid</condition>
  <condition>Anesthesia, Spinal</condition>
  <condition>Aged</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <description>At 5 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <description>At 10 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <description>At 15 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <description>At 20 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T5</arm_group_label>
    <description>At 25 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T6</arm_group_label>
    <description>At 30 minutes after flurbiprofen axetil injected intravenously, 14 patients' samples were required to be collected,including 7 younger patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T7</arm_group_label>
    <description>At 35 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T8</arm_group_label>
    <description>At 40 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T9</arm_group_label>
    <description>At 45 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T10</arm_group_label>
    <description>At 50 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        ASA I or lII, both sexes, aged 18-85 yr
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing lower extremity surgery under spinal or combined spinal-epidural
             anesthesia will be selected.

        Exclusion Criteria:

          -  asthma, liver insufficiency, renal insufficiency, peptic ulcer, allergy to NSAIDs, and
             a history use of NSAIDs within two weeks before operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Feng, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Feng, MD</last_name>
    <phone>08601088325590</phone>
    <email>yifeng65@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Han Yao</last_name>
    <phone>08601088325581</phone>
    <email>yaohan2016@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Feng, MD</last_name>
      <phone>08601088325590</phone>
      <email>yifeng65@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Yi Feng, MD</investigator_full_name>
    <investigator_title>Director of department of anesthesiology and painmanagement</investigator_title>
  </responsible_party>
  <keyword>S-flurbiprofen, R-flurbiprofen</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <keyword>aged</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

